Efficacy and durability of immediate versus delayed single-dose HPV vaccination for persistent infection among young women in Kenya: a randomized, blinded, cross-over clinical trial
Ruanne V. Barnabas·Maricianah A. Onono·Elizabeth A. Bukusi·Betty Njoroge·Rachel L. Winer·Denise A. Galloway·Imeldah N. Wakhungu·Charlene Biwott·Syovata Kimanthi·Kate B. Heller·Meighan Krows·Susan Morrison·Elena A. Rechkina·Stephen Cherne·R. Scott McClelland·Nelly R. Mugo·Elizabeth R. Brown
Abstract Evidence is needed for single-dose human papillomavirus (HPV) vaccine efficacy (VE) durability to support vaccination guidelines. In this randomized crossover trial (NCT03675256), healthy young women aged 15-20 years, recruited through community-based screening in Kenya, were randomly allocated to immediate nonavalent or bivalent HPV vaccination and delayed control at month 30/36 (age 17-23 years), or immediate control and delayed nonavalent HPV vaccination. Cervical swabs collected eve